Analysts’ Weekly Ratings Changes for Aimmune Therapeutics (AIMT)

A number of firms have modified their ratings and price targets on shares of Aimmune Therapeutics (NASDAQ: AIMT) recently:

  • 3/22/2017 – Aimmune Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $38.00 price target on the stock.
  • 3/20/2017 – Aimmune Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
  • 3/15/2017 – Aimmune Therapeutics had its price target lowered by analysts at Piper Jaffray Companies to $38.00.
  • 3/11/2017 – Aimmune Therapeutics had its price target raised by analysts at Piper Jaffray Companies to $40.00. They now have an “overweight” rating on the stock.
  • 2/19/2017 – Aimmune Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $40.00 price target on the stock.
  • 2/17/2017 – Aimmune Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $42.00 price target on the stock.
  • 2/13/2017 – Aimmune Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $40.00 price target on the stock.
  • 2/8/2017 – Aimmune Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $42.00 price target on the stock.

Aimmune Therapeutics Inc (NASDAQ:AIMT) opened at 22.82 on Monday. The stock has a 50 day moving average price of $20.81 and a 200-day moving average price of $19.77. Aimmune Therapeutics Inc has a 1-year low of $9.77 and a 1-year high of $27.31. The company’s market capitalization is $1.15 billion.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Wednesday, March 15th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.08. Equities analysts predict that Aimmune Therapeutics Inc will post ($2.80) earnings per share for the current year.

In other Aimmune Therapeutics news, CFO Warren L. Desouza sold 10,000 shares of the stock in a transaction dated Tuesday, March 21st. The stock was sold at an average price of $22.95, for a total transaction of $229,500.00. Following the completion of the transaction, the chief financial officer now owns 30,681 shares in the company, valued at approximately $704,128.95. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 24.56% of the stock is currently owned by corporate insiders.

Aimmune Therapeutics, Inc, formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

5 Day Chart for NASDAQ:AIMT

Receive News & Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.